SYNTHETIC MORTALITY AND TREATMENT OF CANCER

摘要

1. A method of treating a subject with NMT2 deficient cancer, comprising administering an NMT inhibitor to said subject. The method of claim 1, wherein said NMT inhibitor comprises an NMT1.3 inhibitor. The method of claim 2, wherein said NMT1 inhibitor comprises a small molecule, an antibody, a peptide fragment, a nucleic acid, or combinations thereof. The method of claim 3, wherein said small molecule comprises Tris-DBA, HMA or DDD85646, DDD86481 or derivatives thereof. The method of claim 3, wherein said antibody is a monoclonal antibody or a polyclonal antibody. A method according to claim 3, wherein said nucleic acid contains a dsRNA molecule (double-stranded RNA), an mRNA molecule, a miRNA molecule, a ribozyme, a kshRNA molecule (short hairpin RNA), or an siRNA molecule. The method according to any one of paragraphs. 1-6, wherein said cancer is lymphoma, B-cell lymphoma, follicular lymphoma, diffuse B-large cell lymphoma, mantle cell lymphoma, B-CLL / LL, immunocytoma / Waldenstrom's disease, mucous membrane lymphoma (MALT type) / monocytoid B -cellular lymphoma, Burkitt’s lymphoma, childhood lymphoma, anaplastic large cell lymphoma, acute myeloid leukemia, blast crisis of chronic myeloid leukemia, Burkitt’s lymphoma, plasma cell myeloma, intestinal adenocarcinoma, mixed adenosquamous carcinoma of the lung , small cell lung carcinoma, lung cancer, squamous carcinoma of the esophagus, bone cancer, ductal carcinoma of the breast, diffuse adenocarcinoma of the stomach, medullary carcinoma of the thyroid gland, transient cell carcinoma of the urinary tract, myeloma, clear cell carcinoma of the ovary, transient cell carcinoma of the urine and transient cell carcinoma bladder), chronic myelogenous leukemia (CML),